At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem featuring a Level 4 Robotaxi, eVTOL aircraft Lingxiao models, and Super Intelligent Valet Parking (SIVP). This system aims to seamlessly integrate land and air transport with smart parking and charging infrastructure to reduce travel friction, overcome geographic challenges, and improve efficiency. The eVTOL aircraft are designed to complement ground transport by connecting metropolitan areas and difficult terrains. Chery's strategy focuses on coordinated travel modes rather than speed alone, offering users greater control and flexibility in their journeys through an integrated, automated transport network.
Chery's integrated mobility ecosystem is the subject here, providing context from Pluang's Consumer Cyclical sector data. As of Nov 15, 2026 19:11 WIB, 82 of 134 US stocks rose while 50 fell. Notable movers include PLBY at USD 1.28 with a 4.92% increase and 100% buy order activity, NIO at USD 2.90 down 4.92% with 100% buy orders, and RIVN at USD 12.18 down 4.84%.
At the 2026 Chery International User Summit, Chery introduced a new integrated travel ecosystem combining autonomous Robotaxi, electric vertical takeoff and landing (eVTOL) aircraft, and advanced smart valet parking. This system aims to connect land ...
At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem combining a Level 4 Robotaxi, eVTOL aircraft models Lingxiao Q212 and J506, and a Super Intelligent Valet Parking system. This integrated approach aims to ov...
At the 2026 Chery International User Summit, Chery introduced a connected mobility ecosystem featuring a Level 4 Robotaxi, two eVTOL aircraft models, and a Super Intelligent Valet Parking system. This integrated approach aims to reduce modal transfer...
Lumentum Holdings reported a strong Q1 with revenue up 136.5% year-over-year to $1.26 billion and adjusted operating margins expanding to 42.3%. The company saw a 228.8% increase in systems revenue and generated over $108 million from optical switchi...
Cocrystal Pharma has completed dosing in its Phase 1b challenge study of CDI-988, an antiviral drug targeting norovirus prevention and treatment, with no serious adverse events reported. Preliminary efficacy results are expected near the end of 2026,...
